

4 May 2009

ASX Limited
Adviser, Issuers (Sydney)
Exchange Centre
20 Bridge Street
Sydney NSW 2000

Attention: Emma Badhni

Dear Ms Badhni,


Request for Trading Halt

Pharmaxis Ltd (**Pharmaxis**) requests an immediate trading halt of its securities pending the announcement of results from its Phase III cystic fibrosis clinical trial of Bronchitol.

Pharmaxis requests that the trading halt continue until the commencement of trading on 5 May 2009. Prior to the end of the trading halt Pharmaxis will make another announcement in connection with the clinical trial.

In accordance with ASX Listing Rule 17.1, Pharmaxis confirms that it is not aware of any reason why the trading halt should not be granted.

Yours sincerely,



David McGarvey
Chief Financial Officer/ Company Secretary